Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Discover emerging trends in cancer drug development and the latest treatments with potential to chance clinical care. Secure your seat and benefit from discounted rates!
A dedicated event for the gynae community
How to apply the latest ESMO Guidelines in real-world clinical settings? Join the experts, submit your questions and find out!
Listen to Prof. Alexios Matikas explaining why OncologyPRO is an essential tool to help oncologists in their daily practice, thanks to its accessibility, ease of use, and content depth.
Join the EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research for an inspiring experience and a greater understanding of cancer research!
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Submit your application by 2 February 2023
Applications are open!
Evidence for efficacy is based on the results from the SEQUOIA and ALPINE studies
Findings from the FOxTROT study
Evidence for efficacy is based on the results from the MOUNTAINEER study
ESMO would like to thank the Hellenic Society of Medical Oncologists (HeSMO) for providing translation in the Greek language
Due to the rapid developments in biomarker identification and targeted therapies, a new CPG on oncogene addicted mNSCLC was developed, providing updated recommendations and treatment algorithms on clinically relevant and new biomarker identification, targeting and advanced disease management.
Findings from the FOENIX-CCA2 study
Andrés Cervantes started his two-year mandate as ESMO President on 1 January 2023.
Findings from a correlative analysis of the CALGB 40601 and PAMELA studies in patients with early HER2-positive breast cancer
Findings highlight a complex relationship between immune-related adverse events and clinical outcome
Evidence for efficacy is based on the results from the SEQUOIA and ALPINE studies
Findings from the FOxTROT study
Evidence for efficacy is based on the results from the MOUNTAINEER study
Findings from the FOENIX-CCA2 study
Findings from a correlative analysis of the CALGB 40601 and PAMELA studies in patients with early HER2-positive breast cancer
Findings highlight a complex relationship between immune-related adverse events and clinical outcome
Evidence for efficacy is based on the results from the Study CS-003
An unexpected increase in the number of thromboembolic events observed in crizotinib arm of the ANHL12P1 study
Findings from the KEYNOTE-045 study in patients with platinum-resistant metastatic urothelial cancer and from the KEYNOTE-052 as first-line treatment for cisplatin-ineligible patients
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December.
More than 1.4 million men were diagnosed with prostate cancer in 2020 globally but the molecular characteristics of the disease remain unexplored for the majority of patients around the world.
The ESMO Asia Congress 2022 will be held in person in Singapore and virtually between 2-4 December 2022.
The Molecular Analysis for Precision Oncology Congress 2022 (MAP) is the yearly appointment where leading experts discuss current and future challenges in the rapidly developing field of precision oncology, with the aim of identifying targetable alterations through molecular profiling, to provide the best possible personalised treatment.
Cancer doctors, care providers and payers need to get ready for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment
A novel treatment strategy with personalised cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma
Significant improvement in progression free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumours
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies
Andrés Cervantes started his two-year mandate as ESMO President on 1 January 2023.
With more than 2.2 million new cases and nearly 1.8 million deaths in 2020, lung cancer represents 11.4% of the 19,292,789 new cases of cancer worldwide and 18% of its mortality.
The European Society for Medical Oncology (ESMO) has announced today that the winner of the ESMO Award for Immuno-Oncology 2022 is conferred on Nina Bhardwaj for her outstanding contribution to cancer immunology research.
ESMO has announced today the winners of the 2022 ESMO Society Awards.
ESMO has announced today the results of its Executive Board elections following the closure of the voting system on Monday 27 June 2022.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
ESMO has announced today that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine
Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors
Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone
Different methods – multiparametric biomarker assessment and FDG-PET – show mixed accuracy and their applicability in clinical practice needs to be assessed
A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
Phase III trials are planned to assess combined KRAS G12C inhibition/checkpoint inhibition as first-line therapy
Phase II study indicates that SHR-1701 alone or together with chemotherapy may be a valuable induction strategy in stage III unresectable NSCLC
Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC
However, improved outcomes are reported in PD-L1-positive patients only irrespective of post-operative and post-chemotherapy ctDNA status, calling into question its predictive value
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond
Developed by the ESMO Precision Medicine Working Group, they provide guidance to medical oncologists on the use of circulating tumour DNA assays in clinical practice
The role of polygenic scores for stratified cancer prevention, and the genetic determinants for PSA levels to improve cancer screening utility will be debated during the sixth instalment in the World Cancer Report Updates webinar series.
This year, World Cancer Day is launching #CloseTheCareGap, a three-year campaign aiming to promote awareness, collaboration, and action for a more equitable future in cancer care.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on
With modest progress being made in the gender balance of the oncology field in recent years, women continue to be underrepresented in leadership positions despite making up an increasing proportion of the oncology workforce.
From 2023 ASCO GI Cancers Symposium:
The SUNLIGHT trial shows a significant improvement in the overall survival of patients with refractory metastatic colorectal cancer with the addition of bevacizumab to trifluridine and tipiracil
A reflection on what financial conflict of interests do on single people and what system implications they may have
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
South Africa
South Africa
Virtual Meeting
Spain
Republic of Singapore
United Kingdom
France
Switzerland
Switzerland
Denmark
Switzerland
Argentina
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
